Article Text

Original research
Acceptance of COVID-19 vaccines in Palestine: a cross-sectional online study
  1. Hassan J Zawahrah1,
  2. Hanan Saca-Hazboun2,
  3. Shatha S Melhem3,
  4. Rabee Adwan4,
  5. Ali Sabateen5,
  6. Niveen M E Abu-Rmeileh6
  1. 1 Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
  2. 2 Faculty of Nursing and Health Science, Bethlehem University, Bethlehem, Palestine
  3. 3 Department of Obstetrics and Gynecology, Jordan University of Science and Technology, Irbid, Jordan
  4. 4 Infectious Diseases Unit, Makassed Charitable Society Hospital, East Jerusalem, Palestine
  5. 5 Infectious Diseases Unit, Augusta Victoria Hospital, East Jerusalem, Palestine
  6. 6 Institute of Community and Public Health, Birzeit University, Ramallah, Palestine
  1. Correspondence to Mr Hassan J Zawahrah; hassan.zawahrah{at}


Introduction In Palestine (West Bank and Gaza), there have been more than 320 890 known cases of COVID-19, resulting in 3452 deaths. The detrimental effects of the virus can be seen in the nation’s health, economy and government operations, leading to radical uncertainty that is exacerbated by the absence of any definitive treatment or vaccines. The level of knowledge about and trust in treatment and vaccination varies worldwide. This study aims to assess the willingness of Palestinians to receive a COVID-19 vaccine and their knowledge about such vaccines.

Methods An online survey of adults over 18 years old (n=1080) was conducted in Palestine in October 2020. Using multivariate logistic regression, we identified correlates of participants’ willingness to get a COVID-19 vaccine.

Results We found that about 63% of participants were willing to get a COVID-19 vaccine. However, acceptance varied with the specific demographic variables that were investigated. Women, married participants and those aged 18–24 years are more likely to take the vaccine. Further, participants with good knowledge about the vaccine and its side effects are more willing to get the vaccine.

Conclusion The availability of a safe and effective COVID-19 vaccine in Palestine is crucial to decrease the burden of COVID-19 morbidity and mortality. In addition, to ensure a high vaccination rate, health awareness campaigns should target those who are not willing to get the vaccine, especially those who are more vulnerable and the elderly.

  • COVID-19
  • health policy
  • infection control
  • infectious diseases
  • public health

Data availability statement

Data are available upon reasonable request.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request.

View Full Text

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Contributors Study design by HJZ. Data collection completed by HJZ, HS-H, SSM, RA, AS and NMEA-R. Data analysis and results interpretation were done by NMEA-R and HJZ. Writing the original draft was done by HJZ and HS-H and revised by HJZ, HS-H, SSM and NMEA-R. All authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.